Abstract S58 Table 1

Cost-effectiveness comparisons between different testing strategies and no testing for TB in people living with HIV assuming a 10% progression rate to active TB in people with a positive IGRA

StrategyTotal cost (per 10,000 PHIV in care)Cases active TB prevented (per 10,000 PHIV in care)Incremental cost/case averted (£) compared to no testingIncremental cost/QALY gained (£) compared to no testingIncremental cost/QALY gained compared to previous non-dominated algorithm
No testing£473,137----
BHIVA£538,3545.3£12,205£21,475£21,475
NICE£616,2463.7£38,720£74,790Dominated (simple)
TST in all£725,78116.3£15,511£29,690Dominated (extended)
IGRA in all£892,33014.2£29,571£52,033Dominated (simple)
TST and IGRA in all£1,100,60816.7£37,525£72,943Dominated (extended)
TST, IGRA and CXR in all£1,486,15427.5£36,902£73,558Dominated (extended)
TST, IGRA, CXR and induced
sputum in all
£1,920,74436.6£39,587£79,929Dominated (extended)